JP Morgan Chase
ACRS icon

JP Morgan Chase’s Aclaris Therapeutics ACRS Stock Holding History

JP Morgan Chase’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18,000
Closed -$146K – 6871
2023
Q1 		$146K Buy
+18,000
New +$228K ﹤0.01% 5252

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

JP Morgan Chase's ACRS Position: Q2 2026 in Review

JP Morgan Chase reduced its Aclaris Therapeutics (ACRS) stake by 3.6% in Q2 2026, selling an estimated $78.8K and leaving 468,964 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #4078.

JP Morgan Chase first reported a position in ACRS in Q4 2016 and has held it in 36 quarters since. The position peaked at $7.13M in Q3 2022. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • JP Morgan Chase held 468,964 shares of Aclaris Therapeutics worth $2.35M as of Q2 2026.
  • JP Morgan Chase sold 17,669 Aclaris Therapeutics shares in Q2 2026, an estimated $78.8K.
  • Aclaris Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4078 holding.
  • JP Morgan Chase first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 36 quarters since.
  • JP Morgan Chase's Aclaris Therapeutics position peaked at $7.13M in Q3 2022.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.